Navigation Links
Study Shows Continued Success for New HPV Vaccine Against Virus

A new vaccine aimed at preventing cervical cancer is nearly 100 percent effective against the two types of the human papillomavirus (HPV) responsible for most cases of cervical cancer. Results of a nationwide study of the vaccine will be published in the May 10 issue of the New England Journal of Medicine.

But for the next generation of young women, a series of three shots of a new HPV vaccine marketed by Merck under the name Gardasil could make the difference in preventing cervical cancer. The vaccine targets HPV types 16 and 18, which cause about 70 percent of all cases of cervical cancer. It also targets HPV types 6 and 11, which together cause about 90 percent of all cases of genital warts.

Researchers at more than a dozen international medical centers evaluated the efficacy of quadrivalent vaccine targeting HPV types 6, 11, 16, 18 in more than 12,000 women ages 15 to 26 in 13 countries for nearly three years. They found a near 100 percent efficacy rate in prevention of HPV types 16 and 18.

"It's the first vaccine designed specifically to prevent cancer," says Dr. Ault, one of the authors of the study and a key researcher in the development of the vaccine. "The two main things to emphasize are the vaccine efficacy and the safety. These clinical trials have consistent efficacy around 98 percent. And severe reactions to the vaccine appear to be rare."

According to estimates from the Centers for Disease Control and Prevention (CDC) more than 20 million men and women in the US are infected with HPV, and more than six million new infections are reported each year, making it the most common sexually transmitted disease in the nation.

"Nearly all sexually active people are going to get exposed to the virus sometime during their lives," says Dr. Ault. "For most people, HPV causes no complications and goes away on its own. However, in some cases, if left untreated, certain high-risk types of HPV can l
'"/>




Page: 1 2

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
(Date:7/25/2008)... reduces lung function, increases asthma risk, stu...hDay News) -- A clean, fresh-smelling home may act...pe of cleaning and air freshening products you use...leaning products or air fresheners that contain a ... dicholorobenzene (1,4 DCB), can reduce lung funct...
(Date:7/25/2008)... -- BeaconEquity.com announces the,availability of...tors can view all of the daily trading notes for f...ay,s Trade Alerts include: DUSA Pharmaceuticals In...nc. (Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA),...asdaq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., ...
(Date:7/25/2008)...rketing Exclusivity Begins -, CORONA, Calif., Jul...als, Inc. (NYSE: WPI ), a leading specialty pharm...iary has commenced commercial,shipment of its Omep... 40mg,strength from its Davie, Florida manufacturi...n has 180 days of marketing exclusivity for being ...
(Date:7/25/2008).../ -- The Elekta Family of Companies will,showcase ... the 2008,American Association of Physicists in Me...e joint forces of Elekta, IMPAC and CMS are delive...elivery solutions that,streamline the treatment pr...as well as enhance clinician efficiency., "Our re...
Breaking Medicine News(10 mins):Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3
...Mayfield Dairy Farms announced today that it is vo... Turtle Tracks ice cream with a code date of 4/11...initiated because the affected product contains pe...abel. No other Mayfield Dairy Farms products are i...
...A combination of molecular-targeted therapy and ho...esearch for those seeking an effective treatment ...he International Journal of Gynecological Cancer. ...med the role of hormone therapy in recurrent ovari...
...South Africa is increasing its efforts to prevent ...g appropriate treatments available in the public ...th training, Minister of Social Development Zola S...Tuesday, BuaNews reports. In addition, Skweyiya s...
...Shri E.Ahmed, Minister of State in the Ministry of...hat the Government has decided to introduce e-pass...st these passports will be issued for diplomats ...the end of 2007. Based on the experience gained fr...
Other Medicine News:Health News:South Africa Increasing Efforts To Contain Drug-Resistant TB, Minister Says 2
(Date:7/23/2008)...ound Pharmaceuticals (SPI) has filed,an Investigat...inical,testing of a proprietary formulation of ebs...aring loss or ototoxicity. The oral capsule,contai... stage lung cancer,and head and neck cancer patien...ks the second development program for SPI to enter...
(Date:7/23/2008)...Call/ -- Dendreon Corporation,(Nasdaq: DNDN ) tod...Monitoring Committee (IDMC) to review in October 2...ing to the Company,s Phase 3 IMPACT (IMmunotherapy... as D9902B) clinical trial,of PROVENGE(R) (sipuleu...active cellular immunotherapy for the treatment of...
(Date:7/22/2008)...evelopment Initiative bring MJFF,s,current active ...ry 20,2009, NEW YORK, July 22 /PRNewswire-USNews...of transformative treatments and a cure for Parkin...arkinson,s Research has awarded,$2.7 million in to...ards,were granted under MJFF,s Therapeutics Develo...
(Date:7/22/2008)...Importance to Patients of Passing a ..., Va., July 22 /- Insmed In...ogics and biopharmaceuticals, today,announced that...t at a,Congressional briefing on Friday, July 25th...shing an approval pathway for follow-on,biologics ...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Survey Finds U S Healthcare Facilities Not Doing Enough to Curb MRSA 1044 1Survey Finds U S Healthcare Facilities Not Doing Enough to Curb MRSA 1044 2Survey Finds U S Healthcare Facilities Not Doing Enough to Curb MRSA 1044 3EntreMed Announces FDA Acceptance of IND Application for Panzem 28R 29 in Rheumatoid Arthritis 8090 1EntreMed Announces FDA Acceptance of IND Application for Panzem 28R 29 in Rheumatoid Arthritis 8090 2EntreMed Announces FDA Acceptance of IND Application for Panzem 28R 29 in Rheumatoid Arthritis 8090 3EntreMed Announces FDA Acceptance of IND Application for Panzem 28R 29 in Rheumatoid Arthritis 8090 4Rand study examines the effect of policy on entrepreneurship and small businesses 8089 1Rand study examines the effect of policy on entrepreneurship and small businesses 8089 2Ames Laboratory researchers solve fuel cell membrane structure conundrum 2140 1Ames Laboratory researchers solve fuel cell membrane structure conundrum 2140 2
...Genentech and FDA notified,healthcare professional...acheoesophageal (TE) fistula formation in a recent...ll cell lung,cancer (SCLC). This multicenter, non-...dy combined chemotherapy and radiation plus,Avasti...vents of TE,fistula (one fatal) reported in the fi...
...mence shortly, CARMIEL, Israel, April 18, 2007 /PR...Inc. today announced that it has received,written ...stration,(FDA) that it may initiate a Phase III cl...uct candidate, prGCD, a proprietary plant,cell exp...e (GCD),for the treatment of Gaucher Disease, a l...
Other Medicine Technology:Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 2Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 3
...t reading of entire racks. Its scanner-based image...s in approximately 10 seconds per rack. Decoded tu...of ActiveX controls is provided to allow for integ...HP Scanner and software. Compatible with Windows 2...
Sealed laminate workbench top with powder-coated steel legs. Height is adjustable from 25"-34". Available in hundreds of sizes and configurations. Accessories include shelves, drawers, light fixtures
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color
...cal safety labs (BSL) and pharmaceutical applicati...nd easy sterilization. Panels are precision-joined...wipe down and disinfect. One-inch radius corners s...creates strong, rigid surface without external bra...
Medicine Products: